Vaginal versus intramuscular progesterone for luteal phase support in assisted reproductive techniques: a systematic review and meta-analysis of randomized controlled trials

References

• Kim S-M, Kim J-S. A review of mechanisms of implantation. Dev Reprod. 2017;21(4):351.
   PubMedGoogle Scholar
• Dekel N, Gnainsky Y, Granot I, et al. The role of inflammation for a successful implantation. Am J Reprod Immunol. 2014;72(2):141–147.
   PubMed Web of Science ®Google Scholar
• Simón C, Martı́n JC, and, Pellicer A. Paracrine regulators of implantation. Best Pract Res Clin Obst Gynaecol. 2000;14(5):815–826.
   PubMed Web of Science ®Google Scholar
• Yeung TWY, Chai J, Li RHW, et al. The effect of endometrial injury on ongoing pregnancy rate in unselected subfertile women undergoing in vitro fertilization: a randomized controlled trial. Hum Reprod. 2014;29(11):2474–2481.
   PubMed Web of Science ®Google Scholar
• Casper RF, Yanushpolsky EH. Optimal endometrial preparation for frozen embryo transfer cycles: window of implantation and progesterone support. Fertil Steril. 2016;105(4):867–872.
   PubMed Web of Science ®Google Scholar
• Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89(4):789–792.
   PubMed Web of Science ®Google Scholar
• Yanushpolsky E. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015;33(02):118–127.
   PubMedGoogle Scholar
• Chantilis SJ, Zeitoun KM, Patel SI, et al. Use of Crinone∗ vaginal progesterone gel for luteal support in in vitro fertilization cycles∗∗Crinone 8% (90 mg), Columbia Research Laboratories, Miami, Florida. Fertil Steril. 1999;72(5):823–829.
   PubMedGoogle Scholar
• Yanushpolsky E, Hurwitz S, Greenberg L, et al. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization–embryo transfer cycles: a prospective randomized study. Fertil Steril. 2010;94(7):2596–2599.
   PubMed Web of Science ®Google Scholar
• Unfer V, Casini ML, Costabile L, et al. 17α-Hydroxyprogesterone caproate versus intravaginal progesterone in IVF–embryo transfer cycles: a prospective randomized study. Reprod BioMed Online. 2004;9(1):17–21.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions. Cochrane Book Series. 2008;1:187–241.
   Google Scholar
• Prato LD, Bianchi L, Cattoli M, et al. Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reprod BioMed Online. 2008;16(3):361–367.
   PubMed Web of Science ®Google Scholar
• Abate A, Perino M, Abate FG, et al. Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clin Exp Obstet Gynecol. 1999;26(3–4):203–206.
   PubMedGoogle Scholar
• Beltsos AN, Sanchez MD, Doody KJ, et al. Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support. Reprod Health. 2014;11(1):78.
   PubMedGoogle Scholar
• Devine K, Richter KS, Widra EA, et al. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018;109(2):266–275.
   PubMed Web of Science ®Google Scholar
• Klement AH, Samara N, Weintraub A, et al. Intramuscular versus vaginal progesterone administration in medicated frozen embryo transfer cycles: a randomized clinical trial assessing sub-endometrial contractions. Gynecol Obstet Invest. 2018;83(1):40–44.
   PubMed Web of Science ®Google Scholar
• Moini A, Zafarani F, Eslami B, et al. Comparing intramuscular progesterone, vaginal progesterone and 17-hydroxyprogestrone caproate in IVF and ICSI cycle. Iran J Reprod Med. 2011;9(2):119–124.
   PubMedGoogle Scholar
• Propst AM, Hill JA, Politch J, et al. A prospective, randomized study comparing crinone™ and intramuscular progesterone supplementation in IVF/ET cycles. Fertil Steril. 2000;74(3):S30–S31.
   Google Scholar
• Yanushpolsky E, Hurwitz S, Greenberg L, et al. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89(2):485–487.
   PubMed Web of Science ®Google Scholar
• Wang Y, He Y, Zhao X, et al. Crinone gel for luteal phase support in frozen-thawed embryo transfer cycles: a prospective randomized clinical trial in the Chinese population. PLoS One. 2015;10(7):e0133027.
   PubMed Web of Science ®Google Scholar
• Rashidi BH, Ghazizadeh M, Tehrani Nejad ES, et al. Oral dydrogesterone for luteal support in frozen-thawed embryo transfer artificial cycles: a pilot randomized controlled trial. Asian Pacific J Repro. 2016;5(6):490–494.
   Google Scholar
• Smitz J, Devroey P, Faguer B, et al. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum Reprod. 1992;7(2):168–175.
   PubMed Web of Science ®Google Scholar
• Berjis K, Saremi AT, Moaya M, et al. Comparison of intramuscular and intravaginal progesterone for luteal phase support in IVF cycles: a randomized clinical trial. J Fam Reprod Health. 2008;5(6):99–102.
   Google Scholar
• Chi H, Li R, Qiao J, et al. Vaginal progesterone gel is non-inferior to intramuscular progesterone in efficacy with acceptable tolerability for luteal phase support: a prospective, randomized, multicenter study in China. Eur J Obstet Gynecol Reprod Biol. 2019;237:100–105.
   PubMed Web of Science ®Google Scholar
• Casper RF. Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone? Fertil Steril. 2014;101(3):627–628.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, de Ziegler D, Bulletti C, et al. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95(3):403–406.
   PubMed Web of Science ®Google Scholar
• Blockeel C, Drakopoulos P, Santos-Ribeiro S, et al. A fresh look at the freeze-all protocol: a SWOT analysis. Hum Reprod. 2016;31(3):491–497.
   PubMed Web of Science ®Google Scholar
• Zapantis G, Szmyga MJ, Rybak EA, et al. Premature formation of nucleolar channel systems indicates advanced endometrial maturation following controlled ovarian hyperstimulation. Human Reproduction. 2013;28(12):3292–3300.
   PubMed Web of Science ®Google Scholar
• Shapiro BS, Daneshmand ST, Garner FC, et al. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfer in normal responders. Fertil Steril. 2011;96(2):344–348.
   PubMed Web of Science ®Google Scholar
• Weinerman R, Mainigi M. Why we should transfer frozen instead of fresh embryos: the translational rationale. Fertil Steril. 2014;102(1):10–18.
   PubMed Web of Science ®Google Scholar
• Roque M, Haahr T, Geber S, et al. Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. Hum Reprod Update. 2019;25(1):2–14.
   PubMed Web of Science ®Google Scholar
• Bosdou JK, Venetis CA, Tarlatzis BC, et al. Higher probability of live-birth in high, but not normal, responders after first frozen-embryo transfer in a freeze-only cycle strategy compared to fresh-embryo transfer: a meta-analysis. Hum Reprod. 2019;34(3):491–505.
   PubMed Web of Science ®Google Scholar
• Gonen Y, Powell W, Casper RF, et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metabol. 1990;71(4):918–922.
   PubMed Web of Science ®Google Scholar
• Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;1(10):CD008046.
   Google Scholar
• Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91.
   PubMed Web of Science ®Google Scholar
• Williams SC, Oehninger S, Gibbons WE, et al. Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertil Steril. 2001;76(6):1140–1143.
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta E, Crespo J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010;25(8):2092–2100.
   PubMed Web of Science ®Google Scholar
• Healy MW, Patounakis G, Connell MT, et al. Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles? Fertil Steril. 2016;105(1):93–99.e1.
   PubMed Web of Science ®Google Scholar